Anomalous bone changes in ovariectomized type 2 diabetic rats: inappropriately low bone turnover with bone loss in an estrogen-deficient condition

Aeimlapa, Ratchaneevan; Wongdee, Kannikar; Tiyasatkulkovit, Wacharaporn; Kengkoom, Kanchana; Krishnamra, Nateetip; Charoenphandhu, Narattaphol

doi:10.1152/ajpendo.00093.2019

Cited by 10 publications

(3 citation statements)

References 73 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, various new genes were determined as nanohydroxyapatite target genes including insulin-like growth factor I and II (IGF-I and IGF-II) [60]. Aeimlapa et al [90] commented that IGF-I, which belongs to prominent cytokines for bone formation, is significantly increased in OVX rats. IGF-I induces alkaline phosphatase activity in primary rat calvaria cell culture, and IGF-II elevates alkaline phosphatase activity in human osteoblasts cultures [91,92].…”

Section: Discussionmentioning

confidence: 99%

Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model

Fouad-Elhady

Aglan

Hassan

et al. 2020

Heliyon

View full text Add to dashboard Cite

Osteoporosis is a skeletal degenerative disease characterised by abnormal bone turnover with scant bone formation and overabundant bone resorption. The present approach was intended to address the potency of nanohydroxyapatite (nHA), chitosan/hydroxyapatite nanocomposites (nCh/HA) and silver/hydroxyapatite nanoparticles (nAg/HA) to modulate bone turnover deviation in primary osteoporosis induced in the experimental model. Characterisation techniques such as TEM, zeta-potential, FT-IR and XRD were used to assess the morphology, the physical as well as the chemical features of the prepared nanostructures. The in vivo experiment was conducted on forty-eight adult female rats, randomised into 6 groups (8 rats/group), (1) gonad-intact, (2) osteoporotic group, (3) osteoporotic þ nHA, (4) osteoporotic þ nCh/HA, (5) osteoporotic þ nAg/HA and (6) osteoporotic þ alendronate (ALN). After three months of treatment, serum sclerostin (SOST), bone alkaline phosphatase (BALP) and bone sialoprotein (BSP) levels were quantified using ELISA. Femur bone receptor activator of nuclear factor-kappa B (NF-κB) ligand (RANKL) and cathepsin K (CtsK) mRNA levels were evaluated by quantitative RT-PCR. Moreover, alizarin red S staining was applied to determine the mineralisation intensity of femur bone. Findings in the present study indicated that treatment with nHA, nCh/HA or nAg/HA leads to significant repression of serum SOST, BALP and BSP levels parallel to a significant down-regulation of RANKL and CtsK gene expression levels. On the other side, significant enhancement in the calcification intensity of femur bone has been noticed. The outcomes of this experimental setting ascertained the potentiality of nHA, nCh/HA and nAg/HA as promising nanomaterials in attenuating the excessive bone turnover in the primary osteoporotic rat model. The mechanisms behind the efficacy of the investigated nanostructures involved the obstacle of serum and tissue indices of bone resorption besides the strengthening of bone mineralisation.

show abstract

Section: Discussionmentioning

confidence: 99%

Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model

Fouad-Elhady

Aglan

Hassan

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…При сочетании менопаузы и СД скорость костного обмена имеет свои особенности в силу разнонаправленного влияния дефицита эстрогенов при менопаузе и сложного патогенеза СД. Многие экспериментальные исследования указывают на замедление костного обмена при СД и менопаузе [28][29][30]. Влияние сахароснижающих препаратов на костную ткань в экспериментальных исследованиях довольно широко обсуждается в литературе.…”

Section: Discussionunclassified

Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause

et al. 2023

View full text Add to dashboard Cite

BACKGROUND: Diabetes mellitus (DM) is an independent risk factor for low-traumatic fractures. On the other hand, hypoglycemic drugs can have both positive and negative effects on bone remodeling.THE AIM: Тo investigate bone metabolism parameters during surgical menopause and experimental DM under the treatment with glucagon-like peptide receptor agonist type 1 (arGLP-1) liraglutide (LIRA) and sodium-glucose cotransporter type 2 inhibitor (iSGLT-2) canagliflozin (CANA).MATERIALS AND METHODS: Female Wistar rats have been subjected to bilateral ovariectomy at the beginning of the experiment. Diabetes mellitus (DM) was modelled using a high-fat diet and streptozotocin+nicotinamide. Four weeks after the following groups were formed: “OE+DM” (females after ovariectomy with DM and without any therapy, n=4) «OE+DM+CANA» (females after ovariectomy with DM under treatment with CANA, n=4), «OE+DM+LIRA» (females after ovariectomy with DM under treatment LIRA, n=5). The treatment or observation period were continuing for 8 weeks. Calcium, phosphorus and bone turnover markers (fibroblast growth factor-23 (FGF-23), osteocalcin, sclerostin, osteoprotegerin (OPG), nuclear factor-kappa-B receptor activator ligand (RANKL), were measured in the end of experiment. Bone histomorphometry was performed after euthanasia.RESULTS: Treatment with both CANA and LIRA did not significantly affect the phosphorus-calcium metabolism, sclerostin and osteocalcin concentrations. At the same time, the level of OPG was the highest in «OE+DM ‘’ group (9.1 [7.81; 10.045] pmol/l). The differences were significant compared with «OE+DM+CANA’’ (2, 33 [1.84; 5.84] pmol/l, p = 0.003) and «OE+DM+LIRA» (1.7 [1; 2] pmol/l, p = 0.003) groups. There were no differences in OPG levels between animals treated with different drugs. Similarly, the OPG/RANKL ratio was similarly reduced with both types of treatment. In “OE+DM+CANA’’ group the bone trabeculae number of the femur epiphysis (p=0.042) were decreased in comparison to «OE+DM» group. LIRA did not change the histoarchitectonic parameters.CONCLUSION: Bone metabolism markers did not differ when using as canagliflozin as liraglutide. Besides, canagliflosin can lead to the activation of bone resorption, which is expressed in the femur epiphyseal trabeculae number decreasing.

show abstract

“…Bone microstructural defect in 4-month-old male BKO vs. WT mice was confirmed by bone histomorphometry, using OsteoMeasure system (version 4.10; OsteoMetrics, Atlanta, GA, USA) equipped with Eclipse Ni-U light/fluorescent microscope (Nikon), as previously described 16 , 34 . Trabecular bone microstructural parameters consisted of trabecular bone volume normalized by tissue volume (bone volume fraction, BV/TV; %), trabecular number (Tb.N; mm −1 ), trabecular separation (Tb.Sp; µm) and trabecular thickness (Tb.Th; µm).…”

Section: Methodsmentioning

confidence: 99%

Mild-intensity physical activity prevents cardiac and osseous iron deposition without affecting bone mechanical property or porosity in thalassemic mice

Charoenphandhu

Sooksawanwit

Aeimlapa

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Thalassemia causes anemia, ineffective erythropoiesis, bone loss and iron accumulation in several tissues, e.g., liver, bone and heart, the last of which leads to lethal cardiomyopathy and arrhythmia. Although exercise reportedly improves bone density in thalassemic mice, exercise performance is compromised and might pose risk of cardiovascular accident in thalassemic patients. Therefore, we sought to explore whether mild-intensity physical activity (MPA) with 30–50% of maximal oxygen consumption was sufficient to benefit the heart and bone. Herein, male hemizygous β-globin knockout (BKO) mice and wild-type littermates were subjected to voluntary wheel running 1 h/day, 5 days/week for 3 months (MPA group) or kept sedentary (SDN; control). As determined by atomic absorption spectroscopy, BKO-MPA mice had less iron accumulation in heart and bone tissues compared with BKO-SDN mice. Meanwhile, the circulating level of fibroblast growth factor-23—a factor known to reduce serum iron and intestinal calcium absorption—was increased early in young BKO-MPA mice. Nevertheless, MPA did not affect duodenal calcium transport or body calcium retention. Although MPA restored the aberrant bone calcium-phosphorus ratio to normal range, it did not change vertebral calcium content or femoral mechanical properties. Microstructural porosity in tibia of BKO-MPA mice remained unaltered as determined by synchrotron radiation X-ray tomographic microscopy. In conclusion, MPA prevents cardiac and bone iron accumulation, which is beneficial to thalassemic patients with limited physical fitness or deteriorated cardiac performance. However, in contrast to moderate-intensity exercise, MPA does not improve bone mechanical properties or reduce bone porosity.

show abstract

Anomalous bone changes in ovariectomized type 2 diabetic rats: inappropriately low bone turnover with bone loss in an estrogen-deficient condition

Cited by 10 publications

References 73 publications

Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model

Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model

Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause

Mild-intensity physical activity prevents cardiac and osseous iron deposition without affecting bone mechanical property or porosity in thalassemic mice

Contact Info

Product

Resources

About